Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

109.44 -2.04 (-1.83%)
Streaming Delayed Price Updated: 3:40 PM EST, Nov 4, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biontech Se ADR

< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
64 65 Next >
Pfizer/BioNTech Updated Omicron Adapted COVID-19 Vaccine Shows 4-Fold Higher Neutralizing Activity
Via Benzinga
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
From BioNTech SE
Via GlobeNewswire
BioNTech Shares Up On Hope For Combined Flu, Covid Shot
The shot will combine Pfizer's quadrivalent flu shot with the bivalent Covid booster. 
Via Investor's Business Daily
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
From Pfizer Inc.
Via Business Wire
Pfizer, BioNTech Launch Omicron-Adapted COVID Shot-Flu Combination Vaccine Study
Via Benzinga
Why Inovio Pharmaceuticals Stock Zoomed Nearly 6% Higher Today
The biotech is ceasing its internally funded efforts to develop a heterologous coronavirus booster. 
Via The Motley Fool
A New BioTech Research Race Is Focused On Improving Life For MS Patients
When the world is focused on a global pandemic no one saw coming four years ago, the attention given to escalating diseases with no known cure can be hidden from the public consciousness. This is... 
Via Benzinga
Is BioNTech a Good Long-Term Buy?
BioNTech has a burgeoning oncology portfolio up its sleeve. 
Via The Motley Fool
Are Pfizer and Moderna Stocks Buys With a Potential COVID Surge Coming?
There's still considerable near-term uncertainty for both of these vaccine makers. 
Via The Motley Fool
JP Morgan Maintains Neutral Rating for BioNTech: Here's What You Need To Know
JP Morgan has decided to maintain its Neutral rating of BioNTech (NASDAQ:BNTX) and lower its price target from $183.00 to $132.00. Shares of BioNTech are trading down 0.68% over the last 24 hours, at... 
Via Benzinga
BioNTech to Report Third Quarter 2022 Financial Results and Operational Update on November 7, 2022
From BioNTech SE
Via GlobeNewswire
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday
Gainers Huadi International Group Co., Ltd. (NASDAQ: HUDI) jumped 89.3% to close at $58.92 on Friday. 
Via Benzinga
Moderna, Amazon, Tesla, And Other Big Gainers From Friday
U.S. stocks closed higher on Friday, with the Dow Jones gaining around 750 points. Here is the list of some big stocks recording gains in the previous session. 
Via Benzinga
Why Novavax Stock Rose 12.57% on Friday
Investors did an about-face after the stock slumped earlier in the week. 
Via The Motley Fool
Why Are Vaccine Stocks MRNA, PFE, BNTX, NVAX Up Today?
Vaccine stocks are flying higher on Friday on word that Pfizer will quadruple the price of its Covid-19 vaccine. Will others follow suit? 
Via InvestorPlace
Why Boston Beer Shares Are Trading Higher? Here Are 52 Stocks Moving In Friday's Mid-Day Session
Gainers Altamira Therapeutics Ltd. (NASDAQ: CYTO) surged 67% to $0.5484 after the company announced divestiture of its inner ear development assets. 
Via Benzinga
Twitter Rebuffs Elon Musk Layoff Plans Report, Toyota Cuts 2023's Production Target, Vaccine Makers Expect 3x Price Increase In COVID-19 Shot: Top Stories Friday, Oct. 21
Bloomberg 
Via Benzinga
Vaccine Makers Mull Price Increase For COVID-19 Boosters Amid Falling Demand
Via Benzinga
Boston University's COVID-19 Created In Lab Research Comes Under Scrutiny
Boston University created an artificial form of COVID-19 in a laboratory. Now, U.S. health officials have launched an inquiry into a controversial study. The Boston University research was designed to... 
Via Benzinga
Why Moderna Stock Dropped Today
Competition is intensifying. 
Via The Motley Fool
Why Novavax Stock Couldn't Win on Wednesday
FDA authorization isn't necessarily a slam dunk for a company. 
Via The Motley Fool
European Advisory Committee Backs Pfizer/BioNTech's COVID Shot For Younger Kids
Via Benzinga
Pfizer and BioNTech Receive Positive CHMP Opinion for COMIRNATY® in Children 6 Months to less than 5 Years in the European Union
From BioNTech SE
Via GlobeNewswire
Why BioNTech SE And Novavax Shares Are Diving
BioNTech SE - ADR (NASDAQ: BNTX) and Novavax, Inc. (NASDAQ: NVAX) shares are trading lower by 4.07% to $133.28 and 7.68% to $18.76, respectively, ahead of the close of Tuesday's session. Vaccine stock 
Via Benzinga
3 Supercharged Dividend Stocks to Buy if There's a Stock Market Sell-Off
All three of these medical stocks offer a high-yield dividend. 
Via The Motley Fool
Bulls And Bears Of The Week: Amazon, Tesla, Apple, Meta And Why An Analyst Is Turning Less Positive On 2 Legacy Automakers
Benzinga examined the prospects for many investors' favorite stocks over the past week — here's a look at some of our top stories. 
Via Benzinga
Why Novavax Stock Had an Ugly Friday
Investors ding the biotech's shares one day after it reported quite good news about an experimental vaccine. 
Via The Motley Fool
Pfizer/BioNTech's Updated Omicron Adapted COVID-19 Shot Increases Neutralizing Antibodies Above Pre-Booster Levels
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ:  
Via Benzinga
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
From BioNTech SE
Via GlobeNewswire
Pfizer and BioNTech Announce Positive Early Data From Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older
From Pfizer Inc.
Via Business Wire
< Previous 1 2
...
18 19 20 21 22 23 24 25 26
...
64 65 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.